These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 7745107)

  • 41. Deferiprone: second-line treatment of iron overload in the absence of a better alternative.
    Prescrire Int; 2007 Oct; 16(91):196. PubMed ID: 17926834
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Orally effective iron chelators for the treatment of iron overload disease: the case for a further look at pyridoxal isonicotinoyl hydrazone and its analogs.
    Richardson DR; Ponka P
    J Lab Clin Med; 1998 Oct; 132(4):351-2. PubMed ID: 9794707
    [No Abstract]   [Full Text] [Related]  

  • 43. Deferiprone, an oral iron chelator, ameliorates experimental colitis and gastric ulceration in rats.
    Ablin J; Shalev O; Okon E; Karmeli F; Rachmilewitz D
    Inflamm Bowel Dis; 1999 Nov; 5(4):253-61. PubMed ID: 10579118
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The oral iron chelator deferiprone protects against iron overload-induced retinal degeneration.
    Hadziahmetovic M; Song Y; Wolkow N; Iacovelli J; Grieco S; Lee J; Lyubarsky A; Pratico D; Connelly J; Spino M; Harris ZL; Dunaief JL
    Invest Ophthalmol Vis Sci; 2011 Feb; 52(2):959-68. PubMed ID: 21051716
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Liver iron depletion and toxicity of the iron chelator deferiprone (L1, CP20) in the guinea pig.
    Wong A; Alder V; Robertson D; Papadimitriou J; Maserei J; Berdoukas V; Kontoghiorghes G; Taylor E; Baker E
    Biometals; 1997 Oct; 10(4):247-56. PubMed ID: 9353871
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Chelator-facilitated removal of iron from transferrin: relevance to combined chelation therapy.
    Devanur LD; Evans RW; Evans PJ; Hider RC
    Biochem J; 2008 Jan; 409(2):439-47. PubMed ID: 17919118
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Myocyte damage and loss of myofibers is the potential mechanism of iron overload toxicity in congestive cardiac failure in thalassemia. Complete reversal of the cardiomyopathy and normalization of iron load by deferiprone.
    Kolnagou A; Michaelides Y; Kontos C; Kyriacou K; Kontoghiorghes GJ
    Hemoglobin; 2008; 32(1-2):17-28. PubMed ID: 18274979
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Reduction of body iron stores to normal range levels in thalassaemia by using a deferiprone/deferoxamine combination and their maintenance thereafter by deferiprone monotherapy.
    Kolnagou A; Kleanthous M; Kontoghiorghes GJ
    Eur J Haematol; 2010 Nov; 85(5):430-8. PubMed ID: 20662901
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hepatic and Cardiac Iron-load in Children on Long-term Chelation with Deferiprone for Thalassemia Major.
    Totadri S; Bansal D; Trehan A; Khadwal A; Bhatia A; Sodhi KS; Bhatia P; Jain R; Das R; Khandelwal N
    Indian Pediatr; 2018 Jul; 55(7):573-575. PubMed ID: 30129538
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Iron mobilization from transferrin and non-transferrin-bound-iron by deferiprone. Implications in the treatment of thalassemia, anemia of chronic disease, cancer and other conditions.
    Kontoghiorghes GJ
    Hemoglobin; 2006; 30(2):183-200. PubMed ID: 16798643
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacokinetics of the oral iron chelator deferiprone (L1) in patients with iron overload.
    al-Refaie FN; Sheppard LN; Nortey P; Wonke B; Hoffbrand AV
    Br J Haematol; 1995 Feb; 89(2):403-8. PubMed ID: 7873392
    [TBL] [Abstract][Full Text] [Related]  

  • 52. PCTH: a novel orally active chelator of the aroylhydrazone class that induces iron excretion from mice.
    Wong CS; Kwok JC; Richardson DR
    Biochim Biophys Acta; 2004 Dec; 1739(1):70-80. PubMed ID: 15607119
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Selective iron chelation in Friedreich ataxia: biologic and clinical implications.
    Boddaert N; Le Quan Sang KH; Rötig A; Leroy-Willig A; Gallet S; Brunelle F; Sidi D; Thalabard JC; Munnich A; Cabantchik ZI
    Blood; 2007 Jul; 110(1):401-8. PubMed ID: 17379741
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Objectives and mechanism of iron chelation therapy.
    Hershko C; Link G; Konijn AM; Cabantchik ZI
    Ann N Y Acad Sci; 2005; 1054():124-35. PubMed ID: 16339658
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long-term therapy with deferiprone.
    Olivieri NF
    Acta Haematol; 1996; 95(1):37-48. PubMed ID: 8604585
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Correlation of iron exchange between the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one(L1) and transferrin and possible antianaemic effects of L1 in rheumatoid arthritis.
    Vreugdenhil G; Swaak AJ; de Jeu-Jaspers C; van Eijk HG
    Ann Rheum Dis; 1990 Nov; 49(11):956-7. PubMed ID: 2256752
    [No Abstract]   [Full Text] [Related]  

  • 57. A comparative study of deferasirox and deferiprone in the treatment of iron overload in patients with myelodysplastic syndromes.
    Cermak J; Jonasova A; Vondrakova J; Cervinek L; Belohlavkova P; Neuwirtova R
    Leuk Res; 2013 Dec; 37(12):1612-5. PubMed ID: 23937987
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.
    Tanner MA; Galanello R; Dessi C; Smith GC; Westwood MA; Agus A; Roughton M; Assomull R; Nair SV; Walker JM; Pennell DJ
    Circulation; 2007 Apr; 115(14):1876-84. PubMed ID: 17372174
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Chelation therapy in patients with thalassemia using the orally active iron chelator deferiprone (L1).
    Rombos Y; Tzanetea R; Konstantopoulos K; Simitzis S; Zervas C; Kyriaki P; Kavouklis M; Aessopos A; Sakellaropoulos N; Karagiorga M; Kalotychou V; Loukopoulos D
    Haematologica; 2000 Feb; 85(2):115-7. PubMed ID: 10681716
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia.
    Roberts DJ; Rees D; Howard J; Hyde C; Alderson P; Brunskill S
    Cochrane Database Syst Rev; 2005 Oct; (4):CD004450. PubMed ID: 16235363
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.